Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
TEL AVIV - Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), a clinical-stage biopharmaceutical company with a strong current ratio of 7.42, has identified new pharmacodynamic (PD) blood markers for Aramchol, its leading drug candidate. According to InvestingPro data, while the company maintains more cash than debt on its balance sheet, its stock has declined over 70% in the past year. The discovery, stemming from the Phase 3 ARMOR MASH study, highlights a reduction in chronic systemic inflammation, oxidative stress, and markers associated with atherosclerotic plaque formation, as well as a significant decrease in Atrial Natriuretic Peptide (ANP), a marker for heart failure.
The analysis of blood samples from patients treated with Aramchol revealed these biomarkers, which could serve as early indicators of the drug’s efficacy in treating not only liver conditions like NASH (MASH) but also cardiometabolic diseases. Furthermore, the findings suggest Aramchol may have a role in repressing liver fibrosis through the stimulated expression of the protein KDM4C. With the company’s next earnings report due on May 7, 2025, InvestingPro subscribers can access 10+ additional exclusive insights about Galmed’s financial health and market position.
Galmed’s collaboration with Proteas Health, a leader in protein biomarker and targeted assay development, aims to translate these findings into a cost-effective, high-throughput assay that measures Aramchol’s PD signature. This assay could facilitate real-time evaluation of drug response in future clinical trials, potentially accelerating Aramchol’s development and market entry.
Allen Baharaff, CEO of Galmed, emphasized the significance of the PD markers as a "liquid biopsy" and the potential for Aramchol to explore new avenues in cardiovascular disease research. Dr. Antigoni Manousopoulou of Proteas Health highlighted the importance of targeted PD biomarkers in enhancing drug development and ensuring maximum therapeutic benefit with minimal risk.
The data positions Galmed to potentially broaden its clinical pipeline and address additional cardiometabolic and oncological indications. The ability to monitor Aramchol’s impact through a single blood test could transform clinical development and commercialization strategies, especially given the global burden of cardiometabolic and fibro-inflammatory conditions.
This information is based on a press release statement from Galmed Pharmaceuticals Ltd. While current InvestingPro analysis suggests the stock is undervalued, analysts do not anticipate profitability this year. Discover comprehensive valuation metrics and expert insights with an InvestingPro subscription, helping you make more informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.